Pulmonary Hypertension

The recognition of pulmonary hypertension as a distinct clinical entity evolved over more than a century of advances in cardiovascular physiology, hemodynamic measurement, and molecular biology. Early pathologists noted thickened pulmonary vessel walls in autopsy specimens, but it was not until the development of cardiac catheterization that clinicians could measure pressures in the living pulmonary circulation and define the disease quantitatively. The condition gained urgent public health attention in the 1960s when an epidemic of unexplained pulmonary hypertension was linked to the appetite suppressant aminorex fumarate, prompting the World Health Organization to convene its first expert meeting on the topic. Since then, incremental discoveries in endothelial biology, genetics, and targeted pharmacotherapy have transformed pulmonary hypertension from a uniformly fatal diagnosis into a treatable—though still serious—chronic disease.

The central question driving the study of pulmonary hypertension is deceptively straightforward: why does pressure rise in a vascular bed that normally operates at one-fifth of systemic values, and how does this progressive elevation ultimately cause right ventricular failure? Answering this question requires an integrated understanding of vascular remodeling, vasoactive mediator imbalance, genetic susceptibility, and hemodynamic physiology—topics that form the foundation of this lesson.

Pulmonary hypertension is hemodynamically defined as a mean pulmonary artery pressure (mPAP) greater than 20 mmHg at rest, measured by right heart catheterization. The normal pulmonary circulation is a high-flow, low-resistance, highly compliant system designed to accommodate the entire cardiac output at pressures roughly one-sixth of their systemic counterparts. When this low-pressure equilibrium is disrupted—whether by intrinsic vascular disease, left heart dysfunction, chronic hypoxia, or thromboembolic obstruction—the right ventricle faces an afterload for which it is not architecturally designed. Understanding the core principles below is essential before exploring specific etiologies and classification.

The structural changes depicted above are not merely passive consequences of elevated pressure; they are driven by active cellular processes. Pulmonary artery smooth muscle cells undergo both hypertrophy and hyperplasia in response to growth factors, hypoxia, and shear stress. Endothelial cells proliferate abnormally and may form plexiform lesions—complex, glomeruloid-like vascular structures that are pathognomonic for severe pulmonary arterial hypertension. Adventitial fibroblasts differentiate into myofibroblasts, contributing to perivascular fibrosis and further stiffening of the vessel wall. Additionally, in-situ thrombosis occurs frequently due to endothelial injury and a pro-thrombotic milieu, further occluding the already narrowed lumen. The net result is a progressive, self-reinforcing cycle in which elevated resistance begets further remodeling, which in turn increases resistance—a vicious pathophysiological loop.

The hemodynamics of pulmonary hypertension can be understood through a modified version of Ohm's law applied to the pulmonary circulation. Just as electrical resistance equals voltage divided by current, pulmonary vascular resistance (PVR) is derived from the pressure gradient across the pulmonary vascular bed divided by the cardiac output traversing it. This relationship provides the quantitative foundation for distinguishing pre-capillary from post-capillary disease and for monitoring therapeutic responses.

Three Molecular Pathways in Endothelial Dysfunction

All three major classes of targeted PAH therapies were developed from the understanding of three interconnected endothelial signaling pathways. First, the nitric oxide–cGMP pathway normally promotes vasodilation through soluble guanylate cyclase activation; in PAH, NO bioavailability is reduced, and phosphodiesterase-5 (PDE-5) degrades the downstream messenger cGMP too rapidly. Therapies targeting this pathway include PDE-5 inhibitors (sildenafil, tadalafil) and soluble guanylate cyclase stimulators (riociguat). Second, the prostacyclin pathway mediates vasodilation and antiproliferative effects via cAMP; prostacyclin synthase expression is decreased in PAH endothelium. Prostacyclin analogs (epoprostenol, treprostinil) and the prostacyclin receptor agonist selexipag address this deficit. Third, the endothelin pathway is upregulated in PAH, with endothelin-1 acting as a potent vasoconstrictor and mitogen through ET_A and ET_B receptors; endothelin receptor antagonists (bosentan, ambrisentan, macitentan) block this signaling. Current guidelines recommend combination therapy targeting at least two of these three pathways for patients with Group 1 PAH.

The World Health Organization classification system divides pulmonary hypertension into five groups based on shared pathological findings, hemodynamic characteristics, and treatment responses. This classification is clinically indispensable because therapies proven effective in one group may be ineffective or even harmful in another. For instance, pulmonary arterial vasodilators that benefit Group 1 patients can precipitate pulmonary edema in patients with Group 2 disease (left heart failure), where elevated pulmonary pressures are a passive consequence of downstream congestion. The table and diagram below summarize the key features of each group and their hemodynamic profiles.

The following clinical scenario illustrates how right heart catheterization data are used to diagnose and classify pulmonary hypertension. A 52-year-old woman with progressive dyspnea on exertion undergoes catheterization, yielding the following values: mPAP = 42 mmHg, PAWP = 10 mmHg, CO = 4.0 L/min. Determine whether pulmonary hypertension is present, calculate PVR, classify the hemodynamic profile, and assess functional severity.

Diagnosing pulmonary hypertension requires a systematic approach that integrates clinical suspicion, non-invasive screening, and ultimately invasive hemodynamic confirmation. No single test is sufficient: echocardiography provides an accessible screening estimate but cannot measure mPAP directly, while right heart catheterization remains the gold standard but carries procedural risks and is inappropriate as a first-line screening tool. The table below compares the major diagnostic modalities and their respective strengths and limitations in the evaluation of suspected PH.

While the fundamental hemodynamic framework presented earlier provides a solid clinical foundation, advanced research in pulmonary hypertension increasingly focuses on the concept of right ventricular–pulmonary artery (RV–PA) coupling—the relationship between RV contractility and the afterload imposed by the pulmonary vasculature. This concept recognizes that prognosis in PH depends not merely on how high the pulmonary pressures are, but on how well the right ventricle adapts to those pressures. Two patients with identical mPAP values may have vastly different outcomes if one has a well-coupled, hypertrophied RV while the other has a dilated, uncoupled ventricle.

The approval of sotatercept in 2024 represented a paradigm shift: unlike prior vasodilator-based therapies, sotatercept is a first-in-class activin signaling inhibitor that directly targets vascular remodeling by rebalancing growth-inhibitory (BMP) and growth-promoting (activin/GDF) pathways. Clinical trials demonstrated significant reductions in PVR and improvements in 6-minute walk distance when added to background therapy, suggesting that anti-remodeling strategies may represent the next frontier in PAH treatment. As the field continues to evolve, a deeper understanding of RV biology, metabolic derangements, and genetic susceptibility will likely yield further disease-modifying therapies and move the field beyond its current vasodilator-centric paradigm.